Evidence map›Paper›PMID 40537903›Full record

Trial reportHuman vaccines & immunotherapeutics2025

Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up.

Lili Huang, Xinyi Yang, Hong Li, Zhiqiang Xie, Taotao Zhu, Wangyang You, Zeng Wang, Jiebing Tan, Guangwei Feng, Qingmin Sun and 3 more

Erratum issuedAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Lili HuangVaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, China.
Xinyi YangClinical Research and Development Center, Sinovac Life Sciences Co., Ltd, Beijing, China.
Hong LiBacterial Polysaccharide and Conjugate Vaccine Room Department, National Institutes for Food and Drug Control, Beijing, China.
Zhiqiang XieVaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, China.
Taotao ZhuClinical Research and Development Center, Sinovac Biotech Co., Ltd, Beijing, China.
Wangyang YouVaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, China.
Zeng WangClinical Research and Development Center, Sinovac Biotech Co., Ltd, Beijing, China.
Jiebing TanVaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, China.
Guangwei FengVaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, China.
Qingmin SunClinical Research and Development Center, Sinovac Biotech Co., Ltd, Beijing, China.
Bin WangBacterial Polysaccharide and Conjugate Vaccine Room Department, National Institutes for Food and Drug Control, Beijing, China.
Xing HanClinical Research and Development Center, Sinovac Biotech Co., Ltd, Beijing, China.
Yanxia WangVaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a previous phase 3 clinical trial, a 23-valent pneumococcal polysaccharide vaccine (PPV23) induced robust immune responses in participants aged 2 years and older. We conducted this study to evaluate the immune persistence of a single dose of PPV23 6 years after vaccination. In this follow-up study, 600 participants aged 2 years and older (referred to the age of vaccination) who had received a single dose of either test vaccine or control vaccine in the previous clinical trial were enrolled in a 3:1 ratio. Blood samples were collected to determine anti-capsular immunoglobulin G (IgG) antibody levels against 23 serotypes with enzyme-linked immunosorbent assay (ELISA). A total of 598 subjects were included for immune persistence analysis. Six years after vaccination, the geometric mean concentrations (GMCs) of IgG antibodies to most serotypes remained higher than prior to vaccination in both groups (1.1-1.8 folds vs.1.1-1.7 folds), although there was a significant decrease compared to 28 days. The results suggested PPV23 could provide protection 6 years after vaccination. Considering the significant decrease of antibody level, the revaccination in high-risk population may be needed.

Indexed as

Antibodies, BacterialPneumococcal InfectionsPneumococcal VaccinesAdolescentAdultAgedChildChild, PreschoolEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansImmunoglobulin GMaleMiddle AgedSerogroup23-valent pneumococcal capsular polysaccharide vaccineAntibodies, BacterialImmunoglobulin GPneumococcal VaccinesImmune persistencepneumococcal polysaccharide vaccine

Identifiers

PMID40537903
PMCPMC12184158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.